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ABSTRACT The peptide HlVarg, corresponding to a sequence of 23 amino acid residues at the N-terminus of HIV-1 gp4l
(LAVia strain), has the capacity to destabilize negatively charged large unilamellar vesicles. As revealed by infrared spec-
troscopy, the peptide associated with those vesicles showed conformational polymorphism: in the absence of cations the
main structure was a pore-forming a-helix, whereas in the presence of Ca2+ the conformation switched to a fusogenic,
predominantly extended (3-type structure. Here we show that an extended structure can also be involved in electrically neutral
vesicle destabilization induced by the HIV-1 fusion peptide when it binds the vesicle from the aqueous phase. In the absence
of cations, neutral liposomes composed of phosphatidylcholine, phosphatidylethanolamine, and cholesterol (molar ratio
1:1:1) selected for an extended structure that became fusogenic in a dose-dependent fashion. At subfusogenic doses this
structure caused the release of trapped 8-aminonaphtalene-1 ,3,6-trisulfonic acid sodium salt/p-xylenebis(pyridinium)bromide
from liposomes, indicating the existence of a peptide-mediated membrane destabilizing process before and independent of
the development of fusion. When compared to HIVarg, the fusion activity of HlVala (bearing the R22 -* A substitution) was
reduced by 70%. Fusogenicity was completely abolished when a second substitution (V2 -- E) was included to generate
HlVaIa-E2, a sequence representing the N-terminus of an inactive gp4l. However, the three sequences associated with
vesicles to the same extent, and the three adopted a similar extended structure in the membrane. Whereas 1-(4-trimethyl-
aminophenyl)-6-phenyl-1 ,3,5-hexatriene emission anisotropy was unaffected by the three peptides, DPH emission anisotropy
in membranes was increased only by the fusogenic sequences. Taken together, our observations strongly argue that it is not
an a-helical but an extended structure adopted by the HIV-1 fusion peptide what actively destabilizes cholesterol-containing,
electrically neutral membranes. Moreover, membrane destabilization is modulated by the amino acid sequence in the
extended structure. The effect displayed by the aforementioned V2 -> E substitution suggests that the fusion process
described here could be reflecting a physiologically relevant phenomenon.
INTRODUCTION
Initial exposure to the aqueous medium and further insertion
into target cell membranes of fusion peptides are thought to
play a central role in the fusion mechanism of a wide range
of enveloped viruses (White, 1990; Zimmerberg et al.,
1993). It has been proposed that during the entry process of
HIV-1, its envelope protein gpl2O/41 exposes, upon acti-
vation, the fusion peptide at the N-terminal of gp4l trans-
membrane subunit (Gallaher, 1987; Moore et al., 1993).
Activation of gpl20/41 occurs after interaction with the
primary receptor CD4 and requires the presence of human
cofactors that have just recently been identified as chemo-
kine receptors (Feng et al., 1996; Dragic et al., 1996).
Extrusion of the peptide into the aqueous environment
might also involve functional parts of gp4l that show the
ability to oligomerize through the formation of coiled coils
(Wild et al., 1994; Lu et al., 1995). On the basis of its
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hydrophobic character, it is also postulated that the interac-
tion of the fusion peptide with the lipidic components of the
cell membrane could eventually trigger the actual merging
of the viral and cell membranes via a currently unknown
mechanism (White, 1992).
Based on findings that support the involvement of the
N-terminus of gp41 in human immunodeficiency virus
(HIV) fusion in vivo (Bosch et al., 1989; Freed et al., 1990,
1992), several studies have been addressed to investigate the
putative membrane-destabilizing effects of this sequence by
using representative synthetic peptides and model mem-
branes (Rafalski et al., 1990; Slepushkin et al., 1992; Gor-
don et al., 1992; Martin et al., 1993). We have reported that
the HIV-1 fusion peptide behaves as a fusogen in vesicles
consisting of negatively charged 1-palmitoyl-2-oleoylphos-
phatidylglycerol (POPG) only when Ca2+ or Mg2+ is
present in the medium (Nieva et al., 1994; Pereira et al.,
1995). In the absence of cations, the peptide causes lysis of
dispersed POPG LUVs, probably through the formation of
discrete pores in the membrane. Most interestingly, we
found that the peptide associated with POPG vesicles adopts
different secondary structures, a phenomenon that appears
to be likewise modulated by Ca2+; i.e., in the presence of
Ca2 , under conditions supporting fusion, the peptide
adopts mostly a (3-structure, whereas in the absence of
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cations the pore-forming structure is represented by a pre-
dominant a-helical conformation.
The polymorphic conformational behavior detected for
the HIV- 1 fusion peptide in POPG membranes is not
unique. The conformation of most membrane-interacting
proteins is modulated by the host lipid bilayer (Surewicz et
al., 1992; Banuelos and Muga, 1995). In addition, a wide
range of them appear to be conformationally flexible, and
subtle differences in both the aqueous medium and the lipid
environment can lead to quite different membrane-bound
structures. Among others, examples of membrane-bound
peptides and proteins for which conformational polymor-
phism has been detected are amphiphilic and hydrophobic
signal peptides (Tamm, 1991), apolipoproteins (Taylor et
al., 1993), synthetic model peptides (Lee et al., 1993),
a-lactalbumin (Baniuelos and Muga, 1996), and a-hemoly-
sin (Baka's et al., 1997).
The membrane environment into which the HIV- 1 fusion
peptide should partition in vivo is likely to be better repre-
sented by lipids devoid of a net charge (Aloia et al., 1993).
Furthermore, cholesterol is known to be an important mem-
brane component of both the virion and target cell mem-
branes (Aloia et al., 1988, 1993). The HIV-1 envelope
shows a high cholesterol-to-phospholipid molar ratio that
confers on this membrane the low fluidity environment
necessary for viral stability and infectivity. Consequently, in
this work we have employed LUVs made of zwitterionic
phospholipids and cholesterol as targets for the HIV-1 fu-
sion peptide. Because the peptide could sample different
conformations, depending on the lipid enviroment, we have
evaluated its membrane-associated structure in this system
by means of infrared spectroscopy. We conclude that the
peptide switches from the a-helical conformation adopted
in negatively charged membranes to an extended structure
in neutral membranes containing cholesterol. Moreover,
when folded into this extended structure, the peptide desta-
bilizes isolated vesicles and induces fusion in a sequence-
regulated manner, indicating that this conformation actively
modifies the membrane architecture and that such ability
may be modulated by its chemical structure.
MATERIALS AND METHODS
Materials
Dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine, and the
fluorescent probes N-(7-nitro-benz-2-oxa-1,3-diazol-4-yl)phosphatidyleth-
anolamine (N-NBD-PE) and N-(lissamine rhodamine B sulfonyl)phos-
phatidylethanolamine (N-Rh-PE) were purchased from Avanti Polar Lipids
(Birmingham, AL). 8-aminonaphtalene-1,3,6-trisulfonic acid sodium salt
(ANTS), p-xylenebis(pyridinium)bromide (DPX), 1,6-diphenyl-1,3,5-
hexatriene (DPH), and 1-(4-trimethylaminophenyl)-6-phenyl-1,3,5-
hexatriene (TMADPH) were from Molecular Probes (Junction City, OR).
Cholesterol (CHOL), biscinchoninic acid (BCA), and Triton X-100 were
obtained from Sigma Chemical Co. (St. Louis, MO). All other reagents
were of analytical grade. The sequences representing the N-terminus of the
HIV gp4l, HIVag (AVGIGALFLGFLGAAGSTMGARS; LAVIa strain),
HIVala (AVGIGALFLGFLGAAGSTMGAAS; HTLV-III, BHIO clone),
and HIVala E2 (AEGIGALFLGFLGAAGSTMGAAS; HTLV-III, BHIO
clone-41.2 mutant as defined by Freed et al., 1990) were synthesized as
their C-terminal carboxamides and purified (estimated homogeneity
>90%) by Quality Controlled Biochemicals (Hopkinton, MA). Peptide
stock solutions were prepared in dimethylsulfoxide (DMSO) (spectroscopy
grade).
Vesicle preparation and size determination
Large unilamellar vesicles (LUVs) consisting of dioleoylphosphatidylcho-
line (DOPC), dioleoylphosphatidylethanolamine (DOPE), and cholesterol
(CHOL) (molar ratio, 1:1:1) were prepared according to the extrusion
method of Hope et al. (1985) in 5 mM HEPES, 100 mM NaCl (pH 7.4)
buffer. Internal and external osmolarities were adjusted by adding NaCl.
The osmolarities of all solutions were measured in a cryoscopic osmometer
(Osmomat 030; Gonotec, Berlin, Germany). Lipid concentrations of lipo-
some suspensions were determined by phosphate analysis (Bottcher et al.,
1961). Mean diameter and size distribution of vesicles before and after
peptide addition were measured by quasielastic light scattering with a
Malvern Zeta-Sizer instrument.
Fluorimetric assays for vesicle fusion
and leakage
All fluorescence measurements were conducted at 37°C in thermostatically
controlled cuvettes with a Perkin-Elmer LS50-B spectrofluorimeter. The
medium in the cuvettes was continuously stirred to allow the rapid mixing
of peptide and vesicles. Membrane lipid mixing was monitored using the
resonance energy transfer (RET) assay, described by Struck et al. (1981).
The assay is based on the dilution of N-NBD-PE and N-Rh-PE. Dilution
due to membrane mixing results in an increase in N-NBD-PE fluorescence.
Vesicles containing 0.6 mol% of each probe were mixed with unlabeled
vesicles at a 1:4 ratio. The NBD emission was monitored at 530 nm, with
the excitation wavelength set at 465 nm. A cutoff filter at 515 nm was used
between the sample and the emission monochromator to avoid scattering
interferences. The fluorescence scale was calibrated such that the zero level
corresponded to the initial residual fluorescence of the labeled vesicles, and
the 100% value to complete mixing of all of the lipids in the system. The
latter value was set by the fluorescence intensity of vesicles, labeled with
0. 12 mol% of each of the fluorophores, at the same total lipid concentration
as in the fusion assay. Release of vesicular contents to the medium was
monitored by the ANTS/DPX assay. LUVs containing 12.5 mM ANTS, 45
mM DPX, 20 mM NaCl, and 5 mM HEPES (Ellens et al., 1985) were
obtained by separating the unencapsulated material by gel filtration in a
Sephadex G-75 column eluted with 5 mM HEPES, 100mM NaCl (pH 7.4).
Osmolarities were adjusted to 200 mOsm as described above. Fluorescence
measurements were performed by setting the ANTS emission at 520 nm
and the excitation at 355 nm. A cutoff filter (470 nm) was placed between
the sample and the emission monochromator. The 0% leakage corre-
sponded to the fluorescence of the vesicles at time 0; 100% leakage was the
fluorescence value obtained after the addition of Triton X-100 (0.5% v/v).
Values for the final extent of leakage and fusion were obtained at times at
which the kinetics of the processes leveled off. The shortest times consid-
ered were 5 min for peptide-to-lipid ratios higher than 1:100, and 10 min
for lower ratios.
Peptide binding to vesicles
Peptide binding to vesicles was estimated by flotation analysis of the
peptide-liposome complexes in D20 buffer (5 mM HEPES, 100mM NaCl,
pH 7.4), as detailed by Pereira et al. (1995). Peptide dissolved in DMSO
was added to 1 ml DOPC/DOPE/CHOL LUVs (1 mM) prepared in D20
buffer (peptide-to-lipid ratio 1:100). After overnight incubation at room
temperature, centrifugation of the peptide-lipid complexes in a Beckman
Optima TLX ultracentrifuge in a TL100 rotor (627,000 x g, 120 min) gave
rise to a homogeneous band of vesicles floating on top of the D20 buffer.
The tubes were fractionated from the top, and peptide distribution was
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subsequently quantitated by the BCA assay, according to the instructions of
the manufacturer. The peptide fraction cofloating with vesicles was con-
sidered to be membrane-bound.
Electron microscopy
Peptide-liposome complexes were subjected to flotation in D20 buffer as
described. Samples, collected from either the top (floating fraction) or
bottom (pellet) of centrifuge tubes, were subsequently incubated in copper
grids for 2 min, dried, and finally stained for 1 mn with 1% uranyl acetate.
Electron micrographs were obtained with a JEOL 1200EX II microscope
operated at 120 kV and recorded on Kodak SO-163 film.
Infrared spectroscopy
Measurements were essentially conducted as done by Nieva et al. (1994).
Samples consisted of peptide-lipid complexes obtained in D20 buffer
according to the above flotation protocol. Infrared spectra were recorded in
a Nicolet 520 spectrometer equipped with a DTGS detector. Samples,
containing -4 mg peptide/ml, were placed between two CaF2 windows
separated by 50-,um spacers. Two hundred scans as a sample and 200 scans
as a reference were taken for each spectrum, with a shuttle device. Spectra
were transferred to a personal computer, with which solvent subtraction
and band-position determinations were performed as previously reported
(Arrondo et al., 1994).
Fluorescence anisotropy
Steady-state fluorescence anisotropy of DPH and TMADPH was measured
in a MPF-66 Perkin-Elmer fluorometer. Excitation was at 360 nm and
emission was recorded at 430 nm. A 390-nm cutoff filter was used to
prevent scattered light from reaching the detector. The expression used to
calculate anisotropy (R) contained the grating correction factor (Lakowicz,
1983). Sample turbidity caused a negligible effect on the anisotropy values.
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RESULTS
HlVarg-induced destabilization of DOPC/DOPE/
CHOL vesicles
We first carried out a simultaneous characterization of the
peptide-induced membrane destabilization process (leak-
age, fusion, and size increase) and adopted secondary struc-
ture (infrared spectroscopy). HIVarg-induced leakage and
fusion were detected by the dilution of coencapsulated
fluorescent probes into the medium and the mixing of
membrane lipids, respectively. Leakage of vesicles induced
by peptide addition reflects peptide-membrane interaction.
In Fig. 1 it is shown that HIVarg readily induced the leakage
of small molecules. Leakage was monitored by dequench-
ing of ANTS due to its release from ANTS/DPX containing
vesicles. In the same figure, HIVarg induced-membrane
mixing is demonstrated by employing the RET assay
(Struck et al., 1981), which monitors the increase in NBD
fluorescence after probe dilution from labeled to unlabeled
vesicles in a 1:4 population. Similar results (data not shown)
were obtained by using an assay based on excimer forma-
tion by the lipidic probe Pyrene-PC (Pal et al., 1988). Thus
a fluorophore located at the membrane interface and a
fluorophore immersed in the hydrocarbon matrix monitored
essentially the same lipid mixing event. It is important to
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FIGURE 1 HIVarg fusion peptide-induced DOPC/DOPE/CHOL LUV
destabilization. The peptide was added to vesicle suspensions at 37°C, and
its effects on vesicle stability were compared. Vesicle concentration was
100 ,uAM. Peptide was added at peptide-to-lipid ratios of 1:10 (A), 1:100 (B),
and 1:275 (C). *, Kinetics of leakage of ANTS/DPX. *, Kinetics of
membrane lipid mixing (resonance energy transfer assay).
note that this process was induced by HIVarg in the absence
of cations as opposed to the case of POPG vesicles that only
fused when Ca2+ or Mg2+ was present in the medium
(Nieva et al., 1994).
From these data we can conclude that in the absence of
cations, HIVarg interacted with DOPC/DOPE/CHOL mem-
branes and induced two types of destabilizations, one lead-
ing to the rupture of the permeability barrier and the other to
Pereira et al. 1 979
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fusion. From kinetic traces such as the ones displayed in
Fig. 1, we consistently obtained higher initial leakage rates
than lipid mixing rates at a fixed peptide-to-lipid ratio. In
principle, this could either indicate that permeabilization
preceded fusion in our system or merely reflect differences
inherent in the fluorimetric assays. However, the peptide-
dose effect confirmed that leakage was an event that could
evolve independently of fusion and probably precede it
(Fig. 1 C). The dose effect is better illustrated when we
compare the final extents of both processes as a function of
the peptide-to-lipid ratio. Fig. 2 A shows the increase in the
final extents (see Materials and Methods) of membrane
mixing as compared to leakage of contents with increasing
amounts of peptide. We found that a 1:35 peptide-to-lipid
ratio was required to induce 20% lipid mixing. In compar-
ison, HIVarg induced 20% leakage at a much lower 1:275
peptide-to-lipid ratio. In other words, fusion as compared to
leakage probably had to meet additional requirements in
terms of the amount of bound peptide per vesicle to evolve.
Quasielastic light scattering results further demonstrated the
existence of peptide-induced leakage in the absence of
vesicle size increase. As shown in Fig. 2 A, the increase in
vesicle size paralleled the increase in the amount of fusion.
Increase in particle mean size in a vesicular system can arise
from simple aggregation and/or fusion. From the data in
Fig. 2 A we can deduce that the peptide was able to interact
with isolated vesicles and induce leakage of their contents.
Therefore, permeabilization did not appear to be promoted
as a consequence of mechanical strains imposed by vesicle
aggregation or a leaky fusion process induced by the peptide.
With the aim of elucidating the correct correlation be-
tween the structure adopted by the peptide in the membrane
and the occurrence of leakage, fusion, and size increase,
structural studies were performed on peptide-liposome com-
plexes prepared by mimicking as much as possible the assay
conditions described in Fig. 2 A. Thus HIVarg was added at
370C to DOPC/DOPE/CHOL LUV suspensions with con-
tinuous stirring. After incubation, the mixtures prepared in
D20 buffer were subjected to centrifugation to separate free
peptide from floating vesicles containing the bound peptide
(see below). Fig. 2 B shows the conformation-sensitive
amide I region of the infrared spectra of peptides incorpo-
rated into DOPC/DOPE/CHOL membranes at the approxi-
mate doses that activate leakage (curve a), fusion (curve b),
and both processes simultaneously (curve c). The spectra
display an intense absorption maximum at 1625 cm-' and a
less intense maximum at 1689 cm-1. The ability of Fourier
transform infrared (FTIR) spectroscopy to detect and dis-
criminate 3-like conformations from others (Arrondo et al.,
1993; Surewicz et al., 1993) unambiguously indicates that
the peptide occurs in an extended conformation. Whether it
is a classical antiparallel 13-sheet, or we are dealing with
intermolecularly H-bonded aggregates of extended struc-
ture, cannot be said with certainty. The fact that similar
spectra are found for initial peptide-to-lipid ratios (before
flotation) of 1:800, 1:200, and 1:50 demonstrates that the
composition of the system does not influence peptide con-
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FIGURE 2 (A) Final extents of leakage and fusion (see Materials and
Methods) and concomitant increase of vesicle mean size as a function of
increasing concentrations of HIVarg. *, Membrane mixing; 0, leakage: A,
increase in size. Vesicle concentration was 100 ptM. (B) Fourier transform
infrared (FTIR) spectra of HIVarg incorporated into DOPC/DOPE/CHOL
membranes after external partition from the aqueous phase. The peptide
was added to LUVs at different peptide-to-lipid ratios under the experi-
mental conditions used for the fusion and leakage assays (see Materials and
Methods). Peptide-lipid complexes were subsequently isolated from the
floating fractions after ultracentrifugation in D20 buffer. Curve a: 1:800
peptide-to-lipid ratio; curve b: 1:200 peptide-to-lipid ratio; curve c: 1:50
peptide-to-lipid ratio. The spectra are not drawn to the same scale, to better
show the amide I region (1700-1600 cm-')
formation. Thus the peptide, in these samples, adopted the
same predominant extended structure under conditions
where only leakage or, alternatively, both leakage and fu-
sion can occur (see Fig. 2). The spectra also display an
intense band centered at 1734 cm'- that corresponds to the
C=O stretching vibration of the phospholipid ester bonds.
To further ascertain whether the structural data were
recorded on the peptide population associated with the
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vesicles, we characterized, by means of electron micros-
copy, the resulting fractions after flotation of the peptide-
lipid samples (Fig. 3). As shown by the electron micro-
graphs, the unbound peptide in the precipitates consisted of
fibrillar bundles -500 nm in diameter (Fig. 3 A). The
formation of these aggregates could be at the origin of
peptide inactivation in solution. The results in Fig. 4 illus-
trate the effect of incubating the peptide in solution before
the addition of vesicles on the extent of fusion induced by
HIVarg. After a 30-s incubation in solution, the extent of
lipid mixing induced by the peptide was reduced to less than
one-third, and after 2 min fusion became residual. We
conclude that unbound HIVarg gave rise to aggregates con-
stituting an inactive peptide population. Micrographs of
floating fractions are also shown in Fig. 3, B and C. The
control in the absence of HIVarg shows vesicles of a size in
the range of 100 nm (Fig. 3 B). In contrast, the floating
fraction of samples containing the peptide reveals the pres-
ence of larger vesicles (Fig. 3 C). Importantly, in the latter
sample, no peptide aggregates were seen to be floating with
vesicles. Hence the peptide associated with these vesicles
must adopt discrete structures in membranes that are not
discernible at the experimental magnification. Peptides in
these samples were considered to represent the membrane-
bound fraction and were consequently subjected to struc-
tural characterization as described above.
Sequence substitutions: effects on fusion,
conformation, and membrane interaction
The effect of single substitutions within the peptide se-
quence on fusion and secondary structure of the membrane-
bound peptide was investigated next. R22xA substitution
was located in a position close to the C-terminus of the
peptide and yielded HIVala, which represents the fusion
peptide of the BH1O clone derived from the HTLV-III
strain. In principle, this peptide should be fusogenic. A
further V2xE substitution in the HIVala N-terminus yields
HIValaE2, a fusion peptide representing the 41.2 inactive
mutant described by Freed et al. (1990, 1992). This substi-
tution should cause inactivation of the peptide if our assay
were reflecting any physiologically relevant interaction.
a b c
FIGURE 3 Electron micrographs of the products obtained after flotation
of peptide-vesicle mixtures in D20 buffer. Vesicles (1 mM) were mixed
with HIVarg at a peptide-to-lipid ratio of 1:10, incubated overnight, and
subjected to ultracentrifugation (2 h at 600,000 X g). (a) Pellet fraction; (b)
control, showing floating vesicles in the absence of peptide addition; (c)
floating vesicles after incubation with the peptide. Bar = 100 nm.
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FIGURE 4 HIVarg inactivation in solution. The peptide (2 gtM) was
incubated at increasing time periods in buffer before vesicle addition (100
p,M), and the final extent of the remaining lipid mixing activity was
monitored.
Fig. 5 shows the fusion assays in the presence of DOPC/
DOPE/CHOL LUVs and each of these three peptides at a
1:10 peptide-to-lipid molar ratio, as well as their corre-
sponding membrane-bound secondary structure. FTIR re-
sults in Fig. 5 A demonstrate that in vesicles the three
peptides adopted the same predominant extended structure.
Moreover, from these spectra it can be estimated that the
three peptides bound to vesicles to a similar extent, because
the relative areas of the 1734 cm-' (phospholipids) and
amide I (peptide) bands are roughly the same for the three
samples. The equivalent binding capacity of the three pep-
tides was confirmed by the BCA assay described in Mate-
rials and Methods. According to this assay, at a peptide-to-
lipid ratio of 1:100, 82% of HIVarg, 72% of HIVala, and
72.5% of HIVala E2 bound to vesicles. Lipid mixing kinetics
are compared in Fig. 5 B. HIVarg induced extensive and fast
fusion (initial rate 10%/s; final extent 100%). In compari-
son, HIVala displayed a reduced fusogenic activity (initial
rate 0.2%/s; final extent 35%), and HIVala E2 did not induce
fusion at all, judging from the absence ofNBD dequenching
for up to 10 min. In conclusion, peptides that bound lipid
vesicles to the same extent, adopting essentially identical
secondary structures, displayed completely different fusion
activities.
Thus the above results demonstrate that even if a pre-
dominant extended structure represented the fusion-compe-
tent version in neutral membranes, the ability to adopt this
secondary structure by HIV-1 fusion peptides did not cor-
relate with their fusion capacity. Other factors must be
invoked to explain their dissimilar fusogenicities. In an
attempt to find an explanation for the differences, we looked
next at the effects of the peptides on the structure of the lipid
bilayer.
Information from the interface and hydrocarbon region of
the lipid bilayer was obtained by measuring, respectively,
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sensing the environment of the phospholipid acyl chains.
Results in Fig. 6 A demonstrate that TMADPH emission
anisotropy was almost unaffected by the presence of any of
the peptides. By contrast, as shown in Fig. 6 B, DPH
anisotropy was increased by the presence of HIVarg and
HIVala, but not by the presence of HIVala E2. Therefore,
emission anisotropy by the probe located within the hydro-
carbon matrix was affected exclusively by the fusogenic
peptides. Increase in anisotropy ofDPH fluorescence can be
explained in terms of restriction to the extent and/or rate of
the rotational diffusion (Lakowicz, 1983). The movement
restriction in the DPH environment may indicate that only
the fusogenic peptides penetrated into the membrane to the
level of the hydrocarbon chains (Jones and Gierasch, 1994).
DISCUSSION
Membrane destabilization and
adopted conformation
It seems likely that many conformational changes taking
place in the HIV-1 spike protein gpl20/41 during the entry
process are mainly needed to ensure the extrusion into the
aqueous phase of the fusion peptide in the vicinity of the
target membrane (Moore et al., 1993). Once exposed, the
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FIGURE 5 Effect of sequence substitutions on fusion activity and mem-
brane-associated secondary structure. (A) FT7IR spectra of the vesicle-
associated peptides, HIVarg (a), HIVma (b), and HIVala E2 (c). The peptides
were added to vesicles at a peptide-to-lipid ratio of 1:10. (B) Time courses
of membrane mixing induced by HIVarg (0), HIVala (U), and HIValapE2 (A)
in DOPC/DOPE/CHOL vesicles.
the anisotropy of the fluorescence emission ofDPH and that
its cationic analog TMADPH (Haugland, 1996) as a func-
tion of increasing amounts of peptide. The trimethylammo-
nium substituent in TMADPH acts as a surface anchor that
locates the probe close to the membrane interface. DPH, on
the other hand, resides primarily in the membrane interior,
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FIGURE 6 TMADPH (A) and DPH (B) emission anisotropy as a func-
tion of the peptide-to-lipid ratio. Peptides were added to vesicles (100 ,LM)
containing the probes. HIVag (0), HIVala (U), and HIVala E2 (A)-
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peptide probably must partition into the lipidic core of the
cell membrane to carry out its putative destabilizing func-
tion. One important aspect that has been considered in the
present study is the necessity of mimicking the in vivo
situation as much as possible to characterize the HIVa5g-
membrane interaction. Accordingly, we have paid attention
to several issues. First, the peptide must partition from the
aqueous phase into the membrane to account for the possi-
ble effects of the bilayer interface on the adopted confor-
mation and to exert an eventual membrane destabilization
(Deber and Goto, 1996). Hence we looked at the peptide-
membrane interaction after the external addition of the
peptide to vesicle suspensions. Second, we used LUVs as
targets because the curvature of these vesicles closely re-
sembles that of the plasma membrane. Third, the vesicles
were made of a mixture of phospholipids and cholesterol
representing the uncharged fraction of the putative target
composition. Finally, in an effort to better correlate struc-
ture and function, structural studies were performed on
peptides interacting with membranes under functional con-
ditions, i.e., those at which peptide-induced leakage and
fusion occur. To ensure that we precisely studied the struc-
ture adopted by the membrane-bound peptide population,
we followed a strategy to separate by flotation the unbound
peptide aggregates that most likely represent an inactive
fraction (Fig. 3). Nevertheless, it should be pointed out that
the model system described here is still far from entirely
reflecting the in vivo complexity of the studied interaction.
Factors like additional functionally relevant domains in
gp41, membrane asymmetry, or transmembrane electro-
chemical gradients could also be affecting the interaction of
the HIV-1 fusion peptide with its target membrane under
physiological conditions.
From the results in Figs. 1 and 2 it can be deduced that
HIVarg interaction with neutral vesicles made of DOPC/
DOPE/CHOL induces permeabilization (leakage) and fu-
sion (lipid mixing). In contrast to negatively charged POPG
vesicles (Nieva et al., 1994; Pereira et al., 1995), fusion did
not require the presence of cations to occur in suspensions
of DOPC/DOPE/CHOL vesicles. In POPG vesicles, pep-
tide-induced leakage developed in the absence of cations as
well. However, the leakage detected in the DOPC/DOPE/
CHOL LUV system in the absence of cations seems to
represent a different process. The leakage process in DOPC/
DOPE/CHOL LUV is induced by peptides adopting an
extended conformation in the membrane (Fig. 5), whereas
in POPG vesicles the adopted structure is predominantly
a-helix (Nieva et al., 1994; Pereira et al., 1995). We thus
speculate that the initial leakage in the absence of aggrega-
tion and fusion that occurs in DOPC/DOPE/CHOL LUV
(Fig. 2) might be the expression of the initial membrane
destabilization that leads to fusion being part of the same
process. Bilayer destabilization probably gains intensity
upon binding of more peptides per vesicle, until vesicle
aggregation and eventual fusion ensue. In contrast to the
possible consideration of the peptide as a mere aggregating
the aforementioned leakage process occurring in isolated
vesicles suggests that the peptide is the agent conferring
instability on the membrane, so that fusion can eventually
take place. The observations of DPH polarization (Fig. 6)
would also support this point of view. Moreover, recent
observations by our group argue that the peptide is able to
alter the phase behavior of the lipids, probably by modifying
the membrane intrinsic curvature (Pereira et al., manuscript
in preparation).
Under equilibrium conditions, HIV,,g bound to neutral
DOPC/DOPE/CHOL vesicles displays a FTIR spectrum
compatible with the majority of the peptide being arranged
as an extended structure (Fig. 2 B). Under equivalent mea-
suring conditions (i.e., in the absence of cations), HIVarg
bound to negatively charged POPG vesicles adopted a pre-
dominantly a-helix conformation (Nieva et al., 1994;
Pereira et al., 1995). Thus the peptide shows conformational
polymorphism in the sense that, depending on vesicle com-
position, the peptide may take on different secondary struc-
tures. Selection of distinct conformations depending on the
lipidic environment is characteristic of many membrane-
interacting peptides and proteins (Surewicz et al., 1992).
This effect is probably modulated in our system by the
vesicle surface charge rather than by the presence of defined
lipids, because neutralization of POPG vesicles by Ca21
addition induces the adoption of a f3-structure by the peptide
(Nieva et al., 1994; Pereira et al., 1995). It is well known
that surface pH in negatively charged vesicles is lower than
in bulk solution and that this lower pH can modulate as well
the conformation of bound proteins. Therefore we also
studied the conformation adopted by peptides bound to
uncharged vesicles at pH 5.0. The amide I bands in the
collected spectra at pH 5.0 and pH 7.4 were almost identical
(data not shown), indicating that a pH-driven transition
from an extended to an a-helical conformation is not likely
in our system.
Fig. 2 B also illustrates that the main secondary structure
did not change with the amount of peptide bound to DOPC/
DOPE/CHOL vesicles. This result apparently contradicts
previous FTIR determinations by Rafalsky et al. (1990) and
Gordon et al. (1992) indicating that the peptide is able to
adopt an a-helical arrangement in related membranes at low
doses. Even though subtle differences in membrane com-
position could explain this discrepancy (Rafalsky et al. used
pure POPC vesicles and Gordon et al. isolated lipids, in-
cluding the acidic fraction, from red blood cell ghosts), we
think that the relevant factor might be the sample prepara-
tion method (the above authors' cosolubilized peptide and
lipid before solvent evaporation and hydration, instead of
the method applied in our case).
We conclude that the above-described predominantly ex-
tended structure represents the fusion-active conformation
of HIVarg in DOPC/DOPE/CHOL vesicles. It should be
noted that the FTIR spectra are recorded after fusion has
been completed, and therefore we cannot rule out the exis-
tence of transient conformations, other than the detected
device that puts into contact inherently unstable bilayers,
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extended structure, that might be involved in the fusion
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process. The prevailing assumption that the active confor-
mation of viral fusion peptides was in all cases an a-helical
arrangement (Lear and DeGrado, 1987; Harter et al., 1989;
Takahashi, 1990; Rafalski et al., 1990) was initially ques-
tioned by Gallaher et al. (1992). Since then, additional
evidence suggesting a more complex scenario has become
available. Epand et al. (1992) deduced that the measles virus
fusion peptide adopts mostly a (3-structure in a lipid envi-
ronment. Our results on HIVarg interacting with POPG LUV
in the presence of Ca2+ indicated that a main /3-structure
represents the equilibrium conformation after fusion has
been completed (Nieva et al., 1994; Pereira et al., 1995).
Muga et al. (1994) reported that the putative fusion peptide
of PH-30, a sperm surface protein involved in sperm-egg
fusion, also adopts a predominant /3-conformation when
associated with membranes. Interestingly, these sequences
were initially modeled as sided membrane-interactive a-
helices (White, 1992). More recently, Gray et al. (1996)
have shown by means of combining FTIR and circular
dichroism data that synthetic peptides corresponding to the
wild-type or to several fusogenic and nonfusogenic mutants
of influenza fusion peptide (Steinhauer et al., 1995) con-
tained segments of a-helical and /3-strand conformation.
This relatively new notion of a short amino acid sequence
that adopts a /3-type conformation being able to destabilize
membranes is further supported by recent data obtained for
the antimicrobial peptides defensins interacting with vesi-
cles (White et al., 1995).
In our case FTIR spectroscopy suggests that most prob-
ably the peptide monomers arrange into extended structures
that may be stabilized by either inter- or intramolecular
hydrogen bonding. Formation of the latter structures could
be promoted by interfacial binding of peptide monomers. In
fact, when, to detect sequence segments that could show a
tendency to partition into membrane interfaces, we applied
the hydrophobicity scale developed by Wimley and White
(1996) to our peptide, we found a maximum located be-
tween L7 and L12 (Fig. 7). This internal sequence, contain-
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ing two phenylalanines, could be involved in driving the
peptide partition into the membrane interface.
Membrane destabilization and sequence effects
Correct configuration of the fusion peptide N-terminus ap-
pears to be crucial for the fusogenic function of certain
spike proteins (Freed et al., 1992; Steinhauer et al., 1995).
Several authors have located the N-terminus immersed in
the membrane core after peptide-bilayer interaction (Gor-
don et al., 1992; Luneberg et al., 1995). Our results also
point out the importance of the N-terminus for the HIV-1
fusion peptide interaction with DOPC/DOPE/CHOL LUVs.
The polar amino acid substitution V -> E in position 2,
known to block gp4l activity in vivo (Freed et al., 1992),
renders the peptide unable to fuse neutral membranes. We
previously reported a similar effect in POPG vesicles
(Pereira et al., 1995). The absence of HIValaE2-induced
POPG fusion was correlated with its inability to adopt in the
membrane the /3-structure adopted by HIVala under condi-
tions allowing this process (i.e., in the presence of 5 mM
Ca2+). By contrast, in the present work, nonfusogenic
HIVala E2 peptide in DOPC/DOPE/CHOL LUVs adopted
exactly the same secondary structure as fusogenic HIVarg
and HIVala (Fig. 5). Thus the inability to adopt an extended
/3-strand secondary structure does not explain in this system
the fusion inability displayed by HIVala E2. There must be
additional factors that explain fusogenicity by HIVarg and
HIVaia in comparison with HIVala E2.
Peptides arranged in an extended structure are likely to be
surface-bound to bilayers. However, several findings indi-
cate that the 3-structure adopted by HIV&rg and HIVala
probably penetrates to a certain degree into the bilayer
matrix, whereas the one adopted by HIVala E2 remains as-
sociated with the vesicle surface. Induction of leakage of
aqueous contents from isolated vesicles (Fig. 2) suggests
that the permeability barrier must be altered by a local
HiVala HlVala-E2
0 5 10 15 20 0 5 10 15 20 0 5 10 15 20 25
amino acid
FIGURE 7 Hydropathy plots for HIV rg' HIVala, and HIVala E2. A window of five amino acids was used with the hydrophobicity scale at membrane
interfaces determined by Wimley and White (1996).
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disruption. It is difficult to envisage a molecular mechanism
to describe such a disruption that would not imply a certain
degree of peptide penetration. The ability to induce leakage
probably correlates with fusogenicity, because nonfuso-
genic HIVala-E2 was also unable to induce leakage of con-
tents at any tested peptide-to-lipid ratio (data not shown).
Moreover, fluorescence anisotropy data indicate that
HIVarg and HIVala (but not HIValaE2) increase emission
anisotropy of the hydrophobic core-residing DPH probe. In
a fluid phase, surface interaction of peptides might cause
hindrance in DPH motion through a process of lateral lipid
condensation, i.e., lipid-domain formation. However, such a
process is unlikely to occur in our system, given the com-
position of both model membranes and peptides. In addi-
tion, such a superficial interaction would imply a large
effect on the interface-anchored TMADPH emission anisot-
ropy. As the results displayed in Fig. 6 indicate, that is not
the case. Alternatively, acyl chain motion can be directly
affected by inserted peptides. Signal peptides of the outer
membrane protein A of Escherichia coli that have been
shown to insert into membranes by fluorescence quenching
of Trp (Hoyt and Gierasch, 1991), and to adopt a transmem-
brane orientation by spin-label electron spin resonance
spectroscopy (Sankaram and Jones, 1994), increase DPH
anisotropy in fluid membranes (Hoyt and Gierasch, 1991;
Jones and Gierasch, 1994). An increase in DPH emission
anisotropy correlates with a transmembrane orientation
adopted only by the peptides representing the functional
signal sequences (Jones and Gierasch, 1994). Assuming that
membrane-interacting short sequences may affect DPH an-
isotropy in a similar fashion, our observations in the case of
HIV-1 fusion peptides interacting with DOPC/DOPE/
CHOL vesicles would support the finding that fusion-induc-
ing peptides adopting a predominant 3-structure penetrate
into the membrane to the level of the phospholipid acyl
chains. The ability to penetrate into the hydrophobic core
would emerge as an important factor that might correlate
with fusogenicity in our system. This would also explain, at
least in part, the profound effect of the chemical structure on
the fusogenicity of a peptide adopting a given secondary
structure.
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